亚太肾癌治疗和诊断市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

亚太肾癌治疗和诊断市场按癌症类型(肾癌、透明细胞肾细胞癌、乳头状肾细胞癌、嫌色性肾细胞癌、其他癌症类型)、治疗类别、药理学类别、诊断和地理。

市场快照

Market Snapshot1
Study Period: 2018 - 2026
Base Year: 2021
CAGR: 4.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

预计亚太肾癌治疗和诊断市场在预测期内的复合年增长率为 4.1%。推动亚洲地区市场增长的主要因素是肾癌病例数量的增加和制药公司研发支出的增加。

根据 GLOBOCAN 2018,导致亚洲肾癌病例的主要国家是中国和日本。这些国家是全球肾癌发病率最高的国家之一。此外,根据国际癌症研究机构的数据,2018 年亚洲约有 148,947 例新发肾癌病例,死亡率约为 79,149 例。

此外,生活方式的改变、过度吸烟、饮酒的增加以及由于久坐不动的生活习惯而导致的肥胖症增加导致该疾病的发病率不断增加。因此,由于上述因素,亚太肾癌治疗和诊断市场预计将在预测期内显着增长。

Scope of the report

As per the scope of the report, kidney cancer is a type of cancer that starts in kidney cells. The kidney cancer therapeutics and diagnostics involve therapy and diagnostics methods that are used for the treatment of renal cancer. The Asia-Pacific kidney cancer therapeutics & diagnostics market is segmented by cancer type, therapeutic class, pharmacologic class, diagnostics, and geography.

By Cancer Type
Renal Cancer Carcinoma
Clear Cell Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Chromophobe Renal Cell Carcinoma
Other Cancer Types
By Therapeutic Class
Targeted Therapy
Immunotherapy
By Pharmacologic Class
Angiogenesis Inhibitors
Monoclonal Antibodies
mTOR Inhibitors
Cytokine Immunotherapy (IL-2)
By Diagnostics
Biopsy
Intravenous Pyelogram
CT Scan
Nephro-Ureteroscopy
Ultrasound
Other Diagnostics
Geography
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific

Report scope can be customized per your requirements. Click here.

主要市场趋势

肾癌预计将成为亚太肾癌治疗和诊断市场中增长最快的部分

肾细胞癌 (RCC) 是一种肾癌,起源于输送原发性尿液的肾脏近曲小管内壁。它是最常见的肾癌类型。肾细胞癌主要影响年龄较大的人群,通常在 50 至 70 岁之间。 

推动市场发展的因素包括人们对癌症的认识不断提高、老年人口不断增加以及肾癌发病率上升。根据澳大利亚癌症协会,在 2019 年,估计澳大利亚因肾癌导致的年龄标准化死亡率为每 10 万人中有 3.3 人死亡(男性 4.7 人,女性 2.1 人)。预计肾癌的死亡率会随着年龄的增长而增加,这对市场产生了积极影响。因此,肾癌病例的增加、老年人口的增长以及对癌症的认识是推动这一细分市场的主要因素,并有望在预测期内实现。

APAC kidney cancer key trend 1.png

竞争格局

亚太肾癌治疗和诊断市场具有适度整合的竞争力。产品创新和为开发先进技术而进行的持续研发活动有助于促进市场的增长。目前主导市场的一些公司是拜耳公司、F. Hoffmann-La Roche Ltd、Eisai.Co.Ltd、诺华公司、辉瑞公司、雅培实验室、安进公司和西雅图遗传学公司。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Number of Kidney Cancer Cases

      2. 4.2.2 Increased R&D Expenditure of Pharmaceutical Companies

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost Associated with Treatment

      2. 4.3.2 Preference for Generic Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Cancer Type

      1. 5.1.1 Renal Cancer Carcinoma

      2. 5.1.2 Clear Cell Renal Cell Carcinoma

      3. 5.1.3 Papillary Renal Cell Carcinoma

      4. 5.1.4 Chromophobe Renal Cell Carcinoma

      5. 5.1.5 Other Cancer Types

    2. 5.2 By Therapeutic Class

      1. 5.2.1 Targeted Therapy

      2. 5.2.2 Immunotherapy

    3. 5.3 By Pharmacologic Class

      1. 5.3.1 Angiogenesis Inhibitors

      2. 5.3.2 Monoclonal Antibodies

      3. 5.3.3 mTOR Inhibitors

      4. 5.3.4 Cytokine Immunotherapy (IL-2)

    4. 5.4 By Diagnostics

      1. 5.4.1 Biopsy

      2. 5.4.2 Intravenous Pyelogram

      3. 5.4.3 CT Scan

      4. 5.4.4 Nephro-Ureteroscopy

      5. 5.4.5 Ultrasound

      6. 5.4.6 Other Diagnostics

    5. 5.5 Geography

      1. 5.5.1 Asia-Pacific

        1. 5.5.1.1 China

        2. 5.5.1.2 Japan

        3. 5.5.1.3 India

        4. 5.5.1.4 Australia

        5. 5.5.1.5 South Korea

        6. 5.5.1.6 Rest of Asia-Pacific

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bayer AG

      2. 6.1.2 F. Hoffmann-La Roche Ltd

      3. 6.1.3 Eisai.co.Ltd

      4. 6.1.4 Novartis AG

      5. 6.1.5 Pfizer Inc

      6. 6.1.6 Abbott Laboratories

      7. 6.1.7 Amgen Inc

      8. 6.1.8 Seattle Genetics

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market market is studied from 2018 - 2026.

The Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market is growing at a CAGR of 4.1% over the next 5 years.

Pfizer Inc, F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Eisai.Co.Ltd are the major companies operating in Asia-Pacific Kidney Cancer Therapeutics & Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!